Major Molecular Response Induced by Nilotinib as First Line Treatment in a LMC Patient With Intermediate Sokal Risk

Clinical Management Issues - Italy
doi 10.7175/cmi.v6i2s.1138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Seed SRL

Related search

Complete Molecular Response Induced by Nilotinib in a Patient Previously Treated With Imatinib, Nilotinib and Dasatinib

Clinical Management Issues
MedicineAccountingManagementBusiness
2015English

Nilotinib in Der First-Line Zugelassen

Info Onkologie
2011English

Nilotinib Übertrifft Imatinib in Der First-Line Weiterhin

Info Onkologie
2011English

Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Single Patient Experience

American Journal of Hematology
Hematology
2017English

Development of Myasthenia Gravis in a Patient With Chronic Myeloid Leukemia During Treatment With Nilotinib

Hematology Reports
Hematology
2014English

Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Second Experience

American Journal of Hematology
Hematology
2018English

Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) With Nilotinib as the Second-Line Treatment in Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

P3.15-27 Initial Response to First Line Treatment Is the Best Predictor of the Patient Survival in Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Long-Term Response to First-Line Trabectedin in an Elderly Female Patient With a Metastatic Leiomyosarcoma Unfit for Anthracycline

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy